600329 Stock Overview
Produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥31.67 |
| 52 Week High | CN¥39.05 |
| 52 Week Low | CN¥23.40 |
| Beta | 0.80 |
| 1 Month Change | -5.07% |
| 3 Month Change | 16.09% |
| 1 Year Change | -6.72% |
| 3 Year Change | 6.88% |
| 5 Year Change | 135.99% |
| Change since IPO | 126.21% |
Recent News & Updates
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Could Easily Take On More Debt
Dec 18
Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?
Oct 27Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge
Oct 08Recent updates
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Could Easily Take On More Debt
Dec 18Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?
Oct 27Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge
Oct 08Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio
Jul 26Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Jul 05Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)
Apr 18Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Mar 18Shareholder Returns
| 600329 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.6% | -2.8% | -2.6% |
| 1Y | -6.7% | -3.9% | 9.7% |
Return vs Industry: 600329 underperformed the CN Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: 600329 underperformed the CN Market which returned 9.7% over the past year.
Price Volatility
| 600329 volatility | |
|---|---|
| 600329 Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 600329 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600329's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,619 | n/a | www.jydrt.com.cn |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; and biochemical pharmaceutical products, as well as wholesale and retail sale of medicines. Its products include Suxiao Jiuxin Pills, Jingwanhong Ointment, Biqi Capsules, Shunaoxin Dropping Pills, Zilongjin Tablets, Qingfei Xiaoyan Pills, Huoxiangzhengqi Soft Capsules, Tongmai Yangxin Pills, Weichangan Pills, Qingyan Dropping Pills, Haima Bushen Pills, Angong Niuhuang Pills, Niuhuang Qingxin Pills, Qinggong Shoutao Pills, etc. The company also engages in pharmaceutical commercial logistic services; pharmaceuticals retail; chemical raw materials and preparations; and biomedicine.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Fundamentals Summary
| 600329 fundamental statistics | |
|---|---|
| Market cap | CN¥21.17b |
| Earnings (TTM) | CN¥932.37m |
| Revenue (TTM) | CN¥8.04b |
26.2x
P/E Ratio3.0x
P/S RatioIs 600329 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600329 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.04b |
| Cost of Revenue | CN¥4.30b |
| Gross Profit | CN¥3.74b |
| Other Expenses | CN¥2.81b |
| Earnings | CN¥932.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 46.50% |
| Net Profit Margin | 11.60% |
| Debt/Equity Ratio | 19.8% |
How did 600329 perform over the long term?
See historical performance and comparisonDividends
4.0%
Current Dividend Yield106%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 18:29 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Chengzhi Chen | CGS International |
| Shanshan Li | China Merchants Securities Co. Ltd. |